Fig. 4: ctDNA evaluation in FP-RMS. | npj Precision Oncology

Fig. 4: ctDNA evaluation in FP-RMS.

From: Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression and relapse

Fig. 4

a A FP-RMS clinical timeline with different timepoints throughout the treatment course showing correlation of ctDNA PAX3::FOXO1 fusion reads number with tumor progression. b Box-plot depicting number of fusion reads related to final clinical outcome and timepoint of detection (red, deceased patients; green, alive). FOXO1 fusion read numbers were higher in patients following a poor outcome (n = 7 patients). Chemo, Chemotherapy; XRT, radiotherapy. Center line corresponds to the median; lower and upper hinges correspond to 25th and 75th percentiles; upper and lower whiskers correspond to 1.5 x inter-quartile range.

Back to article page